Jiangsu Jibeier Pharmaceutical Co. Ltd. (688566.SH) Latest Company News

Oct 29, 2026, 08:10 UTC
Jibeier reported third-quarter 2026 revenue of 285 million yuan, up 14.29% year over year, attributable net profit of 76.6798 million yuan, up 61.13%, and adjusted attributable net profit of 75.8993 million yuan, up 62.14%; for the first nine months of 2026, revenue was 775 million yuan, up 9.98%, attributable net profit was 176 million yuan, down 10.66%, and adjusted attributable net profit was 175 million yuan, up 14.15%.
Source:
- finance.sina.cn
Sep 21, 2026, 07:59 UTC
Jibeier Pharmaceutical announced it received an invention patent certificate from the China National Intellectual Property Administration for a synthesis method of hydrogen isotope-labeled vortioxetine, with the company and Shanghai Escat Technology as co-patent holders and Jibeier holding exclusive use rights.
Source:
- finance.sina.cn
Sep 17, 2026, 11:58 UTC
Jibeier Pharmaceutical held an online investor briefing for its 2026 half-year results on September 17, 2026, attended by its chairman, CFO, board secretary and an independent director.
Source:
- wap.eastmoney.com
Aug 27, 2026, 09:10 UTC
Jibeier announced a cash dividend of 2.6 yuan per 10 shares (tax inclusive), totaling 52.2864 million yuan (tax inclusive).
Source:
- finance.sina.cn
Aug 27, 2026, 09:10 UTC
Jibeier announced its first-half 2026 results: revenue of 490 million yuan, up 7.61% year-on-year; net profit attributable to shareholders of 99.2384 million yuan, down 33.54% year-on-year; non-recurring net profit of 99.2669 million yuan, down 6.92% year-on-year.
Source:
- finance.sina.cn
Aug 9, 2026, 07:41 UTC
Jichuan Pharmaceutical's wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd. received drug registration certificates for Pediatric Laxative Granules and Mesalazine Sustained-Release Granules approved and issued by the National Medical Products Administration on August 9, 2026.
Source:
- finance.sina.cn
Jul 29, 2026, 10:20 UTC
Jibeier received a patent certificate for a new taxane compound preparation method from the China National Intellectual Property Administration on 2026-07-28.
Source:
- finance.sina.cn

688566.SH

Jibeier Pharmaceutical held an online investor briefing for its 2026 half-year results on September 17, 2026, attended by its chairman, CFO, board secretary and an independent director.

Jibeier announced a cash dividend of 2.6 yuan per 10 shares (tax inclusive), totaling 52.2864 million yuan (tax inclusive).

Jibeier announced its first-half 2026 results: revenue of 490 million yuan, up 7.61% year-on-year; net profit attributable to shareholders of 99.2384 million yuan, down 33.54% year-on-year; non-recurring net profit of 99.2669 million yuan, down 6.92% year-on-year.

Jichuan Pharmaceutical's wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd. received drug registration certificates for Pediatric Laxative Granules and Mesalazine Sustained-Release Granules approved and issued by the National Medical Products Administration on August 9, 2026.

Jibeier received a patent certificate for a new taxane compound preparation method from the China National Intellectual Property Administration on 2026-07-28.